Acadia Pharmaceuticals ACAD reported second-quarter 2025 earnings of 16 cents per share, which beat the Zacks Consensus ...

Q2 2025 Management View Catherine E. Owen Adams, CEO, stated that "Our second quarter performance reinforces the momentum we're building across all facets of our business from commercial strength to ...

Now, in the wake of the FDA’s September conclusion that no changes were needed and that Nuplazid’s current label adequately describes its risks, the group is again arguing that Nuplazid was ...

Nuplazid’s current black box warning cautions that there is “increased mortality in elderly patients with dementia-related psychosis.” Nuplazid is only approved to treat Parkinson’s ...

Nuplazid could offer an important new therapy for the hallucinations, illusions, and delusions experienced by many people with Parkinson's disease.

Doctors and other experts tell CNN they worried that a new drug, Nuplazid, aimed at treating Parkinson’s disease patients with hallucinations was approved too quickly. Now hundreds of reports of ...

Nuplazid is available as 17mg strength tablets in 60-count bottles. For more information call (844) 422-2342 or visit Nuplazid.com.

Nuplazid is protected through a composition of matter patent that runs to 2021, as well as a use patent in PD to 2026. Investors have raised some concerns about safety, EU-market access and sales.

ACADIA (ACAD) files an sNDA for Nuplazid's potential second indication to treat hallucinations and delusions linked to dementia-related psychosis.

A cadia Pharmaceuticals said Monday that its approved medicine called Nuplazid failed to improve the social and emotional symptoms of schizophrenia in a late-stage clinical trial. The negative ...

Nuplazid recorded sales worth $353.4 million in the first nine months of 2021, reflecting an increase of 10.2% year over year. The company is also developing pimavanserin to treat other ...